PMID- 20739897
OWN - NLM
STAT- MEDLINE
DCOM- 20101104
LR  - 20220408
IS  - 1944-7884 (Electronic)
IS  - 1525-4135 (Linking)
VI  - 55
IP  - 3
DP  - 2010 Nov
TI  - Preventing mother to child transmission of HIV with highly active antiretroviral 
      treatment in Tanzania--a prospective cost-effectiveness study.
PG  - 397-403
LID - 10.1097/QAI.0b013e3181eef4d3 [doi]
AB  - Recent guidelines recommend that all HIV-infected women should receive highly 
      active antiretroviral therapy throughout pregnancy and lactation, irrespective of 
      whether or not they need it for their own health. This strategy for prevention of 
      mother to child transmission (PMTCT) of HIV is more effective than the 
      well-established use of single-dose nevirapine, but it is also a more costly 
      alternative. In this economic evaluation, we use a decision model to combine the 
      best available clinical evidence with cost, epidemiological and behavioral data 
      from Northern Tanzania. We find that a highly active antiretroviral therapy-based 
      PMTCT Plus regimen is more cost effective than the current Tanzanian standard of 
      care with single-dose nevirapine. Although PMTCT Plus is roughly 40% more 
      expensive per pregnant woman than single-dose nevirapine, the expected health 
      benefits are 5.2 times greater. The incremental cost effectiveness ratio of the 
      PMTCT Plus intervention is calculated to be 4062 USD per child infection averted 
      and 162 USD per disability adjusted life year.
FAU - Robberstad, Bjarne
AU  - Robberstad B
AD  - Center for International Health, University of Bergen, Bergen, Norway. 
      bjarne.robberstad@cih.uib.no
FAU - Evjen-Olsen, Bjorg
AU  - Evjen-Olsen B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Anti-HIV Agents/economics/*therapeutic use
MH  - Antiretroviral Therapy, Highly Active/economics/*methods
MH  - Cost-Benefit Analysis
MH  - Female
MH  - HIV Infections/*drug therapy/economics/*prevention & control/transmission
MH  - Humans
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical/economics/*prevention & control
MH  - Pregnancy
MH  - Prospective Studies
MH  - Tanzania
EDAT- 2010/08/27 06:00
MHDA- 2010/11/05 06:00
CRDT- 2010/08/27 06:00
PHST- 2010/08/27 06:00 [entrez]
PHST- 2010/08/27 06:00 [pubmed]
PHST- 2010/11/05 06:00 [medline]
AID - 10.1097/QAI.0b013e3181eef4d3 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2010 Nov;55(3):397-403. doi: 
      10.1097/QAI.0b013e3181eef4d3.